Compare CPBI & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPBI | NSPR |
|---|---|---|
| Founded | 2023 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.8M | 72.1M |
| IPO Year | 2023 | 2009 |
| Metric | CPBI | NSPR |
|---|---|---|
| Price | $17.49 | $1.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 2.1K | ★ 55.0K |
| Earning Date | 06-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | N/A | $57.98 |
| Revenue Next Year | N/A | $95.41 |
| P/E Ratio | $21.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.52 | $1.12 |
| 52 Week High | $17.89 | $2.93 |
| Indicator | CPBI | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 27.44 |
| Support Level | $17.37 | N/A |
| Resistance Level | $17.84 | $2.47 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 54.30 | 34.22 |
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.